Ketamine—New Possibilities in the Treatment of Depression: A Narrative Review
Life November 5, 2021 Mateusz Kowalczyk, Edward Kowalczyk, Paweł Kwiatkowski et al. 16 citations
The SARS-CoV-2 epidemic has increased the number of people experiencing depression, with about one third of the global population affected by mental health symptoms such as depression and anxiety. S-ketamine, approved by the FDA in March 2019 for drug-resistant depression, offers a rapid antidepressant effect, reaching maximum effectiveness within 24 hours and possibly reducing suicidal thoughts. However, further research on its side effects is needed, particularly for individuals prone to psychosis or those using alcohol or psychoactive substances.